ReShape Medical taps Sirtex prez Mangano for CEO
ReShape Medical said today it tapped former Sirtex president Michael Mangano as its new prez and chief executive officer.
During his time at Sirtex, Mangano helped grow the company’s revenue from $34 million to over $130 million. Mangano spoke with MassDevice.com about his time with the company, the learning curve he had of moving from a traditional medical device company to an oncology company and why the cancer market may be ripe for other medtech firms.
“I am looking forward to joining the outstanding team of professionals at ReShape Medical who are working diligently to deliver a non-surgical treatment option that is helping so many who struggle with their weight, finally reclaim their quality of life. The company has experienced significant momentum since receiving FDA approval for the ReShape Dual Balloon. My goal as President and CEO will be to continue to grow the strong customer base, so that more people will have access to this safe and effective non-surgical weight loss treatment,” Mangano said in prepared remarks.
Mangano joined Sirtex in 2010, after a 15-year run at Boston Scientific (NYSE:BSX). During his time with the medical giant, he held a position as director of international distribution management and operated in leadership positions during multiple mergers, acquisitions and divestures.
